Market Overview

2 Reasons Why Cantor Fitzgerald Is Bullish on Strongbridge Biopharma

2 Reasons Why Cantor Fitzgerald Is Bullish on Strongbridge Biopharma
The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering
45 Biggest Movers From Yesterday

Strongbridge Biopharma plc (NASDAQ: SBBP), a commercial-stage biopharma company focusing on therapies for rare disease, is an attractive investment option, according to one analyst.

The Rating

Cantor Fitzgerald analyst Elemer Piros initiated coverage of Strongbridge Biopharma with an Overweight rating and $14 price target.

The Thesis

Strongbridge Biopharma is attractive on two fronts: its ongoing commercialization of the ultra-orphan drug Keveyis in primary periodic paralysis and late-stage development of Recorlev in Cushing's clinical program, Piros said in a Tuesday note. (See Piros' track record here.) 

Success on either front could prove to be a major inflection point for the shares, especially as the shares remain significantly undervalued, Piros said. Over the next 12 months, the company is set up for several key catalysts, including its quarterly Keveyis sales reports and two Phase 3 readouts with Recorlev in 2018, the analyst said. 

The company has the right in team in placing, as it boasts executives with previous experiences in several blue-chip companies and an impressive sales force with experience in orphan organizations, according to Cantor Fitzgerald. The company is well-equipped to successfully relaunch Keveyis following a failed attempt by Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Piros said. 

Recorlev has the potential to become a mainstay treatment of Cushing's syndrome, according to Cantor Fitzgerald. The market for Cushing's has already been validated by rival Corcept Therapeutics Incorporated (NASDAQ: CORT), whose commercial drug Korlym is expected to achieve annual revenues of $157 million to $162 million, Piros said. 

The Price Action

Strongbridge Biopharma stock is up over 166 percent year-to-date.

Related Links:

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

FDA Decisions In November: The Month In Review

Latest Ratings for SBBP

Aug 2018Cantor FitzgeraldMaintainsOverweightOverweight
Aug 2018JMP SecuritiesMaintainsMarket OutperformMarket Outperform
Aug 2018Janney CapitalMaintainsBuyBuy

View More Analyst Ratings for SBBP
View the Latest Analyst Ratings

Posted-In: Cantor Fitzgerald Elemer Piros iAnalyst Color Biotech Health Care Initiation Analyst Ratings General Best of Benzinga


Related Articles (CORT + SBBP)

View Comments and Join the Discussion!
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

3 Discount Retail Stocks To Buy As Industry Evolves

Canada's Building Permits News Offers Trading Opportunity